On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients
-
- Chung‐Feng Huang
- Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
-
- Tyng‐Yuan Jang
- Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
-
- Dae Won Jun
- Department of Internal Medicine Hanyang University Hospital Hanyang University College of Medicine Seoul South Korea
-
- Sang Bong Ahn
- Department of Internal Medicine Nowon Eulji Medical Center Eulji University College of Medicine Seoul South Korea
-
- Jihyun An
- Department of Internal Medicine Hanyang University Guri Hospital Hanyang University College of Medicine Guri South Korea
-
- Masaru Enomoto
- Department of Hepatology Osaka City University Graduate School of Medicine Osaka Japan
-
- Hirokazu Takahashi
- Liver Center Saga University Hospital Saga Japan
-
- Eiichi Ogawa
- Department of General Internal Medicine Kyushu University Fukuoka Japan
-
- Eileen Yoon
- Department of Internal Medicine Hanyang University Hospital Hanyang University College of Medicine Seoul South Korea
-
- Soung Won Jeong
- Department of Internal Medicine Soonchunhyang University Hospital Soonchunhyang University College of Medicine Seoul South Korea
-
- Jae‐Jun Shim
- Department of Internal Medicine Kyung Hee University Hospital Kyung Hee University School of Medicine Seoul South Korea
-
- Jae Yoon Jeong
- Department of Internal Medicine Hanyang University Guri Hospital Hanyang University College of Medicine Guri South Korea
-
- Sung Eun Kim
- Department of Internal Medicine Hallym University Sacred Heart Hospital Hallym University College of Medicine Anyan South Korea
-
- Hyunwoo Oh
- Department of Internal Medicine Uijeongbu Eulji Medical Center Eulji University School of Medicine Uijeongbu South Korea
-
- Hyoung Su Kim
- Department of Internal Medicine Hallym University Kangdong Sacred Heart Hospital Hallym University College of Medicine Seoul South Korea
-
- Yong Kyun Cho
- Department of Internal Medicine Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine Seoul South Korea
-
- Ritsuzo Kozuka
- Department of Hepatology Osaka City University Graduate School of Medicine Osaka Japan
-
- Kaori Inoue
- Liver Center Saga University Hospital Saga Japan
-
- Ka Shing Cheung
- Department of Medicine The University of Hong Kong Hong Kong Hong Kong
-
- Lung Yi Mak
- Department of Medicine The University of Hong Kong Hong Kong Hong Kong
-
- Jee‐Fu Huang
- Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
-
- Chia‐Yen Dai
- Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
-
- Man‐Fung Yuen
- Department of Medicine The University of Hong Kong Hong Kong Hong Kong
-
- Mindie H. Nguyen
- Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
-
- Ming‐Lung Yu
- Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background & Aims</jats:title><jats:p>Gamma‐glutamyl transferase (GGT) has been predictive of chronic hepatitis C‐related hepatocellular carcinoma (HCC) development. Its role in the risk of HCC in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues (NAs) is elusive.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 2172 CHB patients from East Asia were randomized into development and validation groups in a 1:2 ratio. Serum GGT levels before and 6 months (M6) after initiating NAs and the potential risk factors were measured. The primary endpoint was HCC development 12 months after NA initiation.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The annual incidence of HCC was 1.4/100 person‐years in a follow‐up period of 11 370.7 person‐years. The strongest factor associated with HCC development was high M6‐GGT levels (>25 U/L; hazard ratio [HR]/95% confidence interval [CI]: 3.31/2.02‐5.42, <jats:italic>P</jats:italic> < .001), followed by cirrhosis (HR/CI: 2.06/1.39‐3.06, <jats:italic>P</jats:italic> < .001), male sex (HR/CI: 2.01/1.29‐3.13, <jats:italic>P</jats:italic> = .002) and age (HR/CI: 1.05/1.03‐1.17, <jats:italic>P</jats:italic> < .001). Among cirrhotic patients, the incidence of HCC did not differ between those with high or low M6‐GGT levels (<jats:italic>P</jats:italic> = .09). In contrast, among non‐cirrhotic patients, the incidence of HCC was significantly higher for those with M6‐GGT level >25 U/L than for their counterparts (<jats:italic>P</jats:italic> < .001). Cox regression analysis revealed that the strongest factor associated with HCC development in non‐cirrhotic patients was high M6‐GGT levels (HR/CI: 5.05/2.52‐10.16, <jats:italic>P</jats:italic> < .001), followed by age (HR/CI: 1.07/1.04‐1.09, <jats:italic>P</jats:italic> < .001). Non‐cirrhotic elderly patients with high M6‐GGT levels had a similarly high HCC risk as cirrhotic patients did (<jats:italic>P</jats:italic> = .29).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>On‐treatment serum GGT levels strongly predicted HCC development in CHB patients, particularly non‐cirrhotic patients, treated with NAs.</jats:p></jats:sec>
収録刊行物
-
- Liver International
-
Liver International 42 (1), 59-68, 2021-11-29
Wiley
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1360294643857538176
-
- ISSN
- 14783231
- 14783223
-
- データソース種別
-
- Crossref
- KAKEN